Suppr超能文献

儿童骨质疏松症:诊断与治疗注意事项。

Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

机构信息

Servizio di Reumatologia Pediatrica, Azienda Ospedaliera Universitaria "Anna Meyer", viale Gaetano Pieraccini 24, Firenze, 50139, Toscana, Italy.

出版信息

Drugs. 2017 Apr;77(6):679-695. doi: 10.1007/s40265-017-0715-3.

Abstract

Osteoporosis is now increasingly recognized in children due to the increased prevalence of disorders associated with bone loss. Fragility fractures represent the cardinal clinical features of pediatric osteoporosis and children presenting with fragility fractures deserve an accurate assessment to rule out a secondary cause. Indeed, in the pediatric population, a low bone mass is often a consequence of a chronic disease or its treatment; genetic bone disorders represent the cause of only a small fraction of cases. The position statement of the International Society for Clinical Densitometry guides physicians in interpreting densitometric data and making diagnoses of osteoporosis in children. Once a diagnosis of osteoporosis has been made, the aim is to identify children in whom bone status may deteriorate if left untreated. To date, bisphosphonates have represented the mainstay of treatment for pediatric osteoporosis. However, due to the peculiar pathophysiology of osteoporosis in this age group, a pharmacological agent with an anabolic effect on bone may provide clinicians with other therapeutic options in children. Multicenter studies are needed to optimize treatments and define optimal clinical response in treated children.

摘要

由于与骨丢失相关的疾病患病率增加,儿童骨质疏松症现在越来越受到关注。脆性骨折是儿童骨质疏松症的主要临床特征,出现脆性骨折的儿童需要进行准确的评估以排除继发原因。事实上,在儿科人群中,骨量低通常是慢性疾病或其治疗的结果;遗传骨疾病仅占少数病例的原因。国际临床骨密度学会的立场声明指导医生解读骨密度数据并做出儿童骨质疏松症的诊断。一旦做出骨质疏松症的诊断,目的是确定如果不治疗可能会使骨状况恶化的儿童。迄今为止,双磷酸盐一直是儿童骨质疏松症治疗的主要方法。然而,由于该年龄段骨质疏松症的特殊病理生理学,具有骨合成作用的药物可能为临床医生在儿童中提供其他治疗选择。需要多中心研究来优化治疗方法并确定治疗儿童的最佳临床反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验